Search

Fight for Sight to maximise impact by funding solutions-focused research in priority eye conditions

Fight for Sight aims to stop sight loss by funding pioneering research. Rod McNeil takes a look at the Primer Fellowship Awards programme, which provides funding for up to £60,000 for individuals to undertake vision-related research for one year. Among...

Assessing everyday visual function in dry AMD – what matters to the person?

Age-related macular degeneration (AMD) is the primary cause of blindness in the developed world and is accountable for more than one half of sight impairment registrations within England and Wales [1]. AMD is prevalent in people aged 60 years and...

Corporate M&A pace gathers momentum

Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...

Diary from my elective: a Parisian experience

The author explains how a research institute’s dedication to multidisciplinary collaboration helped him to discover a passion for academic ophthalmology. The elective aspect to the final year of a medical degree, through its change of scenery and immersion into another...

Retinal prosthetics: science fiction or a vision for the future?

“Is it a fact – or have I dreamt it – that, by means of electricity, the world of matter has become a great nerve, vibrating thousands of miles in a breathless point of time?” – Nathaniel Hawthorne, The House...

Post-Brexit deal welcomed but leaves future relationship with EU far from settled

Rod McNeil breaks down the impact of the Brexit deal on healthcare in the UK, including medicines regulation, research funding, sharing of information and the ability to work abroad. A disorderly no-deal exit from the European Union (EU) was averted...

Do patient demographics influence AMD clinic attendance during COVID-19 lockdown?

The authors assess the impact of the COVID-19 pandemic on adherence to scheduled clinic appointments among age-related macular degeneration patients in a clinic in North Wales. The COVID-19 pandemic has significantly affected the population, affecting economic and social wellbeing, whilst...

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...

Working smarter not harder: How to transform eyecare delivery in the United Kingdom (part 2)

Are we doing enough to meet the current demands on ophthalmic services? In part two of a two-part series (see Part 1 here), Rosalind Harrison explains how efficiency can be improved by setting up eye services in community hubs. The...

Lost in translation

The article that follows is a collection of reflections and observations by Peter (British) and Nathan (Singaporean) living and working in each other’s countries. Peter Cackett “Best thing about this place is it’s not still full of pompous ex-colonials who...

Stem cell transplantation and pterygium surgery

Pterygium is a benign, fibrovascular overgrowth of bulbar conjunctiva extending onto the cornea and has been associated with ultraviolet (UV) light exposure. The prevalence of pterygium worldwide varies between geographical zones but has been reported to range between three and...

Corneal transplantation in the United Kingdom: are we blind to the challenges that still exist after the Organ Donation Bill?

Corneal transplantation (CT) is a significant treatment option for a huge number of patients in the United Kingdom (UK) [1]. For an individual, CT results in a substantial improvement in quality of life. Penetrating keratoplasty with full thickness grafting has...